Kanan Shah, MD; Patricia Mae G. Santos, MD, MS; Lillian A. Boe, PhD; et al.
JAMA Oncol. 2024;10(11):1503-1510. doi:10.1001/jamaoncol.2024.3645
This cross-sectional study of data from the Agency for Healthcare Research and Quality’s Healthcare Cost and Utilization Project National Inpatient Sample investigates whether housing status is associated with the receipt of inpatient care and outcomes among hospitalized adults with cancer who are experiencing homelessness.
Catherine A. O’Connor, BS; Emily Harrold, MD; David Lin, MS; et al.
has audio
JAMA Oncol. 2024;10(11):1511-1518. doi:10.1001/jamaoncol.2024.3651
This cross-sectional study examines clinicogenomic features of Lynch syndrome and characterizes responses to immune checkpoint blockade therapy.
-
Podcast:
Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer
Mahmoud Yousef, MD, MS; Abdelrahman Yousef, MD; Saikat Chowdhury, PhD; et al.
JAMA Oncol. 2024;10(11):1519-1529. doi:10.1001/jamaoncol.2024.3666
This single-center cohort study examines the association of molecular, socioeconomic, and clinical covariates with race and ethnicity disparities in overall survival among patients with colorectal cancer.
-
Invited Commentary
Contributions to Colorectal Cancer Disparities
John M. Carethers, MD
JAMA Oncol
Naifei Chen, MD, PhD; Chengfei Pu, BS; Lingling Zhao, MD, PhD; et al.
open access
JAMA Oncol. 2024;10(11):1532-1536. doi:10.1001/jamaoncol.2024.3891
This nonrandomized clinical trial examines the safety and efficacy of guanylate cyclase-C (GCC) chimeric antigen receptor T-cell therapy in patients with metastatic colorectal cancer.
Soyoung Kwak, PhD; Chan Wang, PhD; Mykhaylo Usyk, PhD; et al.
JAMA Oncol. 2024;10(11):1537-1547. doi:10.1001/jamaoncol.2024.4006
This prospective case-control study nested in 3 large, well-established, prospective US cohorts examines whether the oral bacterial and fungal microbiome is associated with subsequent head and neck squamous cell cancer risk.
Chi Leung Chiang, MD; Kenneth Sik Kwan Chan, PhD; Keith Wan Hang Chiu, MBChB; et al.
JAMA Oncol. 2024;10(11):1548-1553. doi:10.1001/jamaoncol.2024.4085
This cohort study examines 3-year survival among patients with hepatocellular carcinoma placed on a watch-and-wait protocol after achieving complete remission with combined locoregional therapy and immunotherapy.
Carrie Ye, MD, MPH; William D. Leslie, MD, MSc; Saeed Al-Azazi, MSc; et al.
JAMA Oncol. 2024;10(11):1554-1560. doi:10.1001/jamaoncol.2024.4318
This retrospective cohort study assesses the prognostic value of the Fracture Risk Assessment Tool (FRAX) for incident fractures in patients with cancer.